Brief: Nabriva Publishes Data Demonstrating The Potent Anti-Inflammatory Properties Of Xenleta (Lefamulin)
04/10/2021 21:13
Oct 4 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA PUBLISHES DATA DEMONSTRATING THE POTENT
ANTI-INFLAMMATORY PROPERTIES OF XENLETA® (LEFAMULIN)
* NABRIVA - IN NONCLINICAL STUDY OF INFLAMMATORY LUNG
DISEASE,
XENLETA POTENTLY INHIBITED INFLAMMATION CAUSED BY MIGRATION OF
NEUTROPHILS IN MICE
Source text for Eikon: ID:nGNX1xZ84z
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update